There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...

Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Mersana Therapeutics Inc (NASDAQ:MRSN) is set to release its Q4 2024 earnings on March 3, 2025. The consensus estimate for Q4 ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first ...

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...